Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Curevac N.V. (NQ: CVAC )

2.560 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Curevac N.V.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
- Study continues to progress according to protocol following first interim analysis at 59 eligible COVID-19 cases - Sequencing data to be made available in parallel with efficacy data given... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
- First-Generation COVID-19 vaccine program, CVnCoV - Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities - Phase 2a trial in Peru and Panama assessing third booster... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
The Battle Over Covid Vaccine Patents Begins — What It Could Mean For Biotech
Experts say a patent waiver for coronavirus shots wouldn't just pressure Covid vaccine stocks, it could also staunch innovation for biotech companies. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Why CureVac's Stock Is Trading Higher Today
CureVac (NASDAQ:CVAC) shares are trading higher ... 
Via Benzinga
CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study
CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-... 
Via Benzinga
Exposures COVID-19
CureVac: Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
- Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK - CV2CoV mRNA shows high levels of antigen production in rat model - Fast onset of strong... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
What's Up WIth BioNTech Stock And CureVac Stock Today?
BioNTech SE - ADR (NASDAQ: BNTX) shares were trading higher by 8.27% at $198.80 in Monday’s premarket session after the company announced a Chinese joint venture to... 
Via Benzinga
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine... 
Via Talk Markets
Exposures COVID-19
70 Biggest Movers From Friday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday. Velocity Financial, Inc. (NYSE: VEL) rose 36.6% to close at $12.50 following Q1... 
Via Benzinga
32 Stocks Moving in Friday's Pre-Market Session
Gainers Assertio Holdings, Inc. (NASDAQ: ASRT) shares rose 44.2% to $0.7190 in pre-market trading after the company reported better-than-expected Q1 results. iBio, Inc. (NYSE:... 
Via Benzinga
56 Stocks Moving In Friday's Mid-Day Session
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 77% to $4.321. Regional Health Properties, Inc. (NYSE: RHE) gained 43% to $21.40 after dropping 23% on Thursday.... 
Via Benzinga
Bill And Melinda Gates' Divorce News A Bull Case For GameStop? What You Need To Know
A post by a member of the Reddit investor forum r/GME in March that speculated billionaires were increasing their short positions in GameSt... 
Via Benzinga
CureVac's Vaccine Might Protect Against the South African Variant
The promising data in mice needs to translate into humans. 
Via The Motley Fool
Exposures COVID-19
Could These 3 Brilliant mRNA Stocks Make You Millions?
Probably not, but at least one of them could make you thousands over time. 
Via The Motley Fool
Exposures COVID-19
Best Biotech Stocks & ETFs for mRNA, Gene Editing
2020 was the most challenging year in decades but it was great for scientific innovation, particularly in the biotech space. 
Via Talk Markets
CureVac's Potential Has Wall Street Sending Mixed Signals
The biotech still has a long way to go to prove itself and justify its current stock valuation. 
Via The Motley Fool
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2021
Upgrades Susquehanna upgraded the previous rating for Axalta Coating Systems Ltd (NYSE:AXTA) from Neutral to Positive. The current stock performance of Axalta Coating Sys... 
Via Benzinga
2 Reasons This COVID Vaccine Latecomer Could Gain Major Market Share
A big market is in big need of more vaccines. 
Via The Motley Fool
Exposures COVID-19
7 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic
- Rolling submission to accelerate time to marketing authorization of CVnCoV in Switzerland - Review process started with submission of first CVnCoV data package TÜBINGEN, GERMANY and BOSTON, MA /... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
CureVac (CVAC) Q4 2020 Earnings Call Transcript
CVAC earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why PPD, Immunic, Inovio and CureVac Shares Are Higher Today
PPD, Inc. (NASDAQ: PPD), Immunic, Inc. (NASDAQ: IMUX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and CureVac N.V. (NASDAQ: CVAC) are among the healthcare movers on Thursday. PPD... 
Via Benzinga
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
- COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase... 
From CureVac
Via AccessWire
Topics Initial Public Offering Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
22 Stocks Moving in Thursday's Pre-Market Session
Gainers Assertio Holdings, Inc. (NASDAQ: ASRT) rose 25.1% to $0.6485 in pre-market trading. Bit Digital, Inc. (NASDAQ: BTBT) rose 15.1% to $16.40 in pre-market trading after... 
Via Benzinga
Earnings Scheduled For April 15, 2021
Companies Reporting Before The Bell • Charles Schwab (NYSE:SCHW) is projected to report quarterly earnings at $0.82 per share on revenue of $4.58 billion. •... 
Via Benzinga
UK Trial On Mix-Match COVID-19 Vaccines Expanded To Add Moderna, Novavax Shots
Researchers said that a U.K. study of using different Covid-19 vaccines in two-dose inoculations is now expanded to include vaccines made by Moderna Inc (NASDAQ: ... 
Via Benzinga
Exposures COVID-19
South African Variant Able To Elude Pfizer/BioNTech' Vaccine Protection, Israeli Study Shows: Report
According to a real-world data study in Israel, the coronavirus variant discovered in South Africa may dodge the protection provided by Pfizer Inc (NYSE: PFE) /... 
Via Benzinga
Exposures COVID-19
CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 9, 2021 / CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Government, Officials Defend AstraZeneca's COVID-19 Shot: CNBC
The British government and health experts in the country have come forward to defend the COVID-19 vaccine developed by AstraZeneca plc’s (NASDAQ: AZN) and... 
Via Benzinga
Exposures COVID-19
Europe's Drug Watchdog Concludes Possible Link Between AstraZeneca COVID-19 Vaccine And Blood Clots
The European Medicines Agency (EMA), after an in-depth analysis, has concluded that unusual blood clots should be listed as a “very rare side effect” of the... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.